恩替卡韦联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎的临床疗效  

Clinical efficacy of entecavir thymosin α1 in HBe Ag positive chronic hepatitis B

作　　者：黄平[1] 王海[1] 黄江秀 杨高雄[1] Huang Ping et al(Department of Infectious Diseases, Lianjiang Municipal People＇s Hospital, Lianjiang 524400, Chin)

机构地区：[1]廉江市人民医院感染内科,广东524400

出　　处：《齐齐哈尔医学院学报》2016年第28期3538-3540,共3页Journal of Qiqihar Medical University

摘　　要：目的探讨恩替卡韦联合胸腺肽α1治疗HBe Ag阳性慢性乙型肝炎的临床疗效,为后期的医治提供参考。方法选取本院自2014年2月至2016年5月期间收治的HBe Ag阳性慢性乙型肝炎患者120例作为研究对象,依据不同的治疗方法,按照随机数字表法将患者分为观察组和对照组各60例。对照组患者采用恩替卡韦治疗,观察组则在对照组基础上给联合胸腺肽α1进行治疗。结果经治疗后,观察组患者的治疗总有效率(90.0%)高于对照组(71.7%);而治疗后HBe Ag/HBe Ab血清转换率、HBe Ag阴转率相关抗病毒疗效指标,对照组相对于观察组显著偏高;两组的组间数据具有明显差异(P<0.05)。同时ALT复常率、HBVDNA阴转率、不良反应差异结果无统计学意义,P>0.05。结论对HBe Ag阳性慢性乙型肝炎进行恩替卡韦联合胸腺肽α1的治疗,能提高临床疗效,在治疗中起到显著作用,值得进一步推广使用。Objective To evaluate the clinical efficacy of entecavir thymosin α1 in HBe Ag-positive chronic hepatitis B,provide a reference for later treatment. Methods HBe Ag-positive chronic hepatitis B patients in our hospital from February 2014 to May 2016 period were treated 120 patients for the study,based on different methods of treatment,according to the random number table were divided into groups and the control 60 cases in each group. The control group was treated with entecavir treatment; the observation group gave thymosinα1 treatment on the basis of the control group. Results After treatment,the total effective rate of patients in the observation group（ 90.0%） was higher（ 71.7%）; and after treatment HBe Ag / HBe Ab seroconversion,HBe Ag negative rate associated antiviral efficacy endpoint,the relative control group in the observation group was significantly higher; data of two groups had a significant difference（ P〈0. 05）. While ALT normalization,HBVDNA negative rate of adverse reactions showed no statistically significant difference,P〉0.05. Conclusion： In HBe Ag positive chronic hepatitis B,entecavir combined with uct alpha 1 treatment,can improve the clinical efficacy,play a significant role in treatment,worthy of further promotion. Conclusions

关 键 词：胸腺肽Α1 恩替卡韦 HBEAG阳性慢性乙型肝炎 

分 类 号：R512.620.5[医药卫生—内科学]